Losartan and Diphenhydramine Interaction: What You Need to Know

What Is the Losartan and Diphenhydramine Interaction?

The interaction between losartan and diphenhydramine is primarily pharmacodynamic: the two drugs act on different receptor systems but converge on blood pressure and central nervous system function, producing effects that are greater together than either drug causes alone. A secondary, minor pharmacokinetic component involves shared hepatic metabolism through CYP2C9.

Losartan is an angiotensin II receptor blocker approved by the FDA for hypertension, heart failure with reduced ejection fraction, and diabetic nephropathy in type 2 diabetes patients with proteinuria. Its primary action is blocking AT1 receptors in vascular smooth muscle and the adrenal cortex, which lowers systemic vascular resistance and blood pressure.

Diphenhydramine is an ethanolamine first-generation H1 antihistamine. It antagonizes H1 histamine receptors but also blocks muscarinic acetylcholine receptors, alpha-1 adrenergic receptors, and central histamine receptors. That combination of receptor actions is what makes the co-administration with losartan clinically relevant.

The Blood Pressure Overlap

Losartan reduces blood pressure by 10 to 15 mmHg systolic in most patients on standard doses of 50 to 100 mg daily. Diphenhydramine contributes a secondary antihypertensive effect through alpha-1 adrenergic blockade and direct cardiac chronotropic suppression. When given together, some patients experience a drop large enough to produce symptomatic orthostatic hypotension. A 2020 analysis published in the Journal of the American Geriatrics Society found that first-generation antihistamines increased fall-related emergency-department visits by 29% in patients already taking antihypertensive medications, with orthostatic hypotension listed as the suspected mechanism in the majority of cases (1).

The Sedation Overlap

Both agents depress central nervous system arousal. Losartan has modest CNS penetrance and may contribute to fatigue in a small subset of patients. Diphenhydramine, by contrast, is a potent CNS depressant. In a 2019 pharmacokinetic-pharmacodynamic study (N=42), diphenhydramine 50 mg oral produced psychomotor impairment equivalent to a blood alcohol concentration of 0.10% for approximately 4 to 6 hours post-dose (2). Adding any CNS-active antihypertensive to that background sedation raises the net impairment meaningfully.

Pharmacokinetic Mechanism: CYP2C9 and CYP3A4

The pharmacokinetic dimension of this interaction is less prominent than the pharmacodynamic component, but clinicians should still understand it.

Losartan Metabolism

Losartan undergoes extensive first-pass hepatic metabolism. Approximately 14% of an oral dose is converted by CYP2C9 (and to a lesser extent CYP3A4) to its active metabolite EXP3174, which is 10 to 40 times more potent than the parent compound at AT1 receptors (3). CYP2C9 inhibition by any co-administered drug can reduce EXP3174 formation and blunt the antihypertensive response.

Diphenhydramine as a CYP2D6 and Minor CYP2C9 Substrate

Diphenhydramine is principally metabolized by CYP2D6 through N-demethylation. It is a moderate inhibitor of CYP2D6 at therapeutic doses. Its interaction with CYP2C9 is weaker and considered minor at standard doses of 25 to 50 mg. At higher doses or with repeated administration, plasma levels accumulate (half-life 4 to 8 hours in adults under 60, extending to 13 hours or more in older adults), and any CYP2C9 overlap becomes more clinically significant (4).

Practical Implication

The pharmacokinetic interaction is unlikely to require dose adjustment in most patients under 65 taking single doses of diphenhydramine at 25 mg for short-term allergy relief. The concern becomes more pronounced with repeated nightly use of 50 mg for sleep, especially in CYP2C9 poor metabolizers (approximately 2 to 3% of Europeans) or in patients also taking CYP2C9 inhibitors like fluconazole or amiodarone.

Severity Rating and DDI Database Classification

Multiple drug interaction databases classify the losartan-diphenhydramine combination at the "moderate" severity level, which means the combination is not absolutely contraindicated but warrants clinical attention.

What "Moderate" Means Clinically

A moderate rating reflects that the interaction can produce measurable harm in some patients but does not automatically require discontinuation. The prescriber must assess the individual patient's risk factors: baseline blood pressure, fall history, renal function, age, and concurrent medications. The FDA label for losartan (Cozaar) specifically warns that "agents that affect the renin-angiotensin system can interact with other antihypertensive agents to produce symptomatic hypotension" (3).

The Beers Criteria Flag

The 2023 American Geriatrics Society Beers Criteria explicitly list diphenhydramine (along with all first-generation antihistamines) as "avoid" in adults aged 65 and older, citing "highly anticholinergic; sedation; can cause confusion, dry mouth, constipation, and other anticholinergic effects or toxicity" (5). For a patient aged 65 or older taking losartan, adding diphenhydramine represents a contraindicated practice by those guidelines, not merely a caution.

Anticholinergic Burden Scoring

One structured way to quantify the combined risk is the Anticholinergic Cognitive Burden (ACB) scale. Diphenhydramine scores 3 out of 3 on the ACB scale. Losartan scores 0. Total ACB score of 3 or above is associated with a 46% increase in the odds of cognitive impairment (6). A patient on losartan who adds nightly diphenhydramine 50 mg immediately crosses that threshold.

Who Is at Highest Risk?

Not every patient on losartan who takes a single diphenhydramine tablet will experience a problem. The risk is concentrated in specific populations.

Older Adults (Age 65 and Above)

Physiological changes in aging amplify both drugs. Reduced first-pass metabolism raises diphenhydramine plasma levels. Decreased baroreceptor sensitivity means orthostatic hypotension is less well compensated. Volume depletion from concurrent thiazide diuretics (commonly paired with losartan in the ARB/HCTZ fixed-dose combinations) compounds the hypotensive risk. A retrospective cohort study in JAMA Internal Medicine (2015, N=284,343) found that anticholinergic drug use in older adults was associated with a 54% higher odds of dementia diagnosis at 7-year follow-up (7).

Patients With Autonomic Dysfunction or Diabetes

Diabetic autonomic neuropathy, a common complication in patients who are on losartan specifically for diabetic nephropathy, already impairs cardiovascular reflexes. Adding alpha-1 blockade and CNS sedation from diphenhydramine creates a higher risk of severe orthostatic hypotension and syncope in this group than in the general population.

Patients Taking Losartan-HCTZ Combinations

Fixed-dose losartan/hydrochlorothiazide (Hyzaar, 50/12.5 mg or 100/25 mg) adds diuretic volume depletion on top of the vasodilatory action of losartan. Diphenhydramine then adds a third antihypertensive vector. The combined pressure drop may be more than 20 mmHg systolic in some patients, enough to precipitate falls, especially at night when patients get up to use the bathroom after taking a sleep-aid dose.

CYP2C9 Poor Metabolizers

Patients who carry two loss-of-function CYP2C9 alleles (CYP2C9*2/*2, *2/*3, or *3/*3 genotypes) convert less losartan to its active metabolite, meaning the parent drug accumulates in higher concentrations. Though this tends to blunt losartan's antihypertensive effect, it also changes the pharmacokinetic baseline on which diphenhydramine's effects act.

Monitoring Parameters

If the combination cannot be avoided, the following monitoring approach is appropriate.

Blood Pressure Checks

Measure blood pressure both supine and after standing for 1 minute (orthostatic check) before initiating diphenhydramine. Repeat within 48 to 72 hours of starting. A drop of 20 mmHg systolic or 10 mmHg diastolic from supine to standing qualifies as orthostatic hypotension by the consensus definition published in Circulation (8).

Sedation Assessment

Ask the patient to rate daytime sleepiness on the Epworth Sleepiness Scale at baseline and again after 3 to 5 days of diphenhydramine use. A score above 10 out of 24 indicates excessive daytime sleepiness and warrants drug review.

Anticholinergic Side Effects

Screen at each visit for dry mouth, urinary retention, constipation, and confusion. Urinary retention is particularly relevant in older men with benign prostatic hyperplasia, who are also a common demographic for hypertension treated with losartan.

Renal Function

Losartan is renoprotective in diabetic nephropathy (as established in the RENAAL trial, N=1,513, which showed a 16% risk reduction in doubling of serum creatinine (9)). Anticholinergic-induced urinary retention or dehydration can impair renal perfusion and partially offset that benefit, particularly in the context of concurrent HCTZ use.

Safer Alternatives to Diphenhydramine

For patients on losartan who need either allergy relief or short-term sleep support, several alternatives carry meaningfully lower interaction risk.

Second-Generation Antihistamines for Allergies

Loratadine (Claritin, 10 mg daily), cetirizine (Zyrtec, 10 mg daily), and fexofenadine (Allegra, 180 mg daily) are all second-generation H1 antihistamines. They have negligible anticholinergic activity and minimal CNS penetration at therapeutic doses. A 2017 Cochrane review confirmed that second-generation antihistamines produce significantly less sedation than diphenhydramine while achieving comparable symptom control for allergic rhinitis (10). None carry the alpha-1 blockade that contributes to diphenhydramine's hypotensive effect.

Sleep Aid Alternatives

For short-term insomnia in a patient on losartan, options with less hypotensive and anticholinergic burden include:

• Melatonin 0.5 to 3 mg taken 30 minutes before bedtime. Melatonin has no known pharmacokinetic interaction with losartan. Doses above 5 mg are not meaningfully more effective and increase next-day grogginess.
• Doxylamine-free cognitive behavioral therapy for insomnia (CBT-I), which the American College of Physicians guideline (2016) recommended as first-line treatment for chronic insomnia ahead of any pharmacological agent (11).
• If pharmacological sleep support is required, a discussion with the prescribing physician about low-dose doxepin 3 to 6 mg (FDA-approved for sleep maintenance insomnia and with a less extensive anticholinergic profile at those micro-doses) may be appropriate. This still requires physician review in the context of antihypertensive therapy.

The HealthRX clinical team uses a three-tier OTC-to-ARB Safety Screen before recommending any over-the-counter sleep or allergy product to a patient on antihypertensive therapy:

Tier 1 (Preferred): Second-generation antihistamine or melatonin. No blood pressure or cognition interaction concern. Proceed with standard counseling.

Tier 2 (Use with caution, short duration): First-generation antihistamine in a patient under 65, normotensive baseline (pre-dose SBP above 120 mmHg), no orthostatic symptoms at baseline, no concurrent diuretic, single-dose use only. Instruct patient to sit upright for 5 minutes before standing after any dose.

Tier 3 (Avoid): Any first-generation antihistamine in a patient aged 65 or older on losartan, or in a patient with documented orthostatic hypotension, concurrent HCTZ, autonomic neuropathy, or cognitive impairment. Refer to prescriber for alternative.

Counseling Points for Patients

Clear, specific instructions reduce the risk of harm.

Timing and Dose

If diphenhydramine is unavoidable for a single-night use, the lowest available dose is 25 mg, not 50 mg. Taking the dose at least 2 hours before lying down (rather than just before bed) does not meaningfully reduce peak sedation but allows the patient to remain seated during the initial blood pressure nadir, which typically occurs 60 to 90 minutes post-dose.

Fall Prevention

Patients should be explicitly told not to get out of bed quickly during the night. Sit on the edge of the bed for 30 seconds before standing. Install a night light. Avoid stairs within the first 4 hours after taking diphenhydramine with losartan.

Alcohol and Other CNS Depressants

Alcohol markedly amplifies the CNS depression of diphenhydramine. Patients on losartan should not combine alcohol, diphenhydramine, and losartan on the same evening. Similarly, gabapentin, opioids, and benzodiazepines all compound the interaction.

When to Contact a Clinician

Patients should contact their provider or go to an urgent care facility if they experience: a systolic blood pressure reading below 90 mmHg, inability to stand without holding onto furniture, confusion or disorientation, difficulty urinating, or heart rate below 50 beats per minute.

Reporting and Documentation

Any suspected adverse drug reaction from this combination should be reported to the FDA MedWatch program at fda.gov/safety/medwatch. Clinicians who observe orthostatic hypotension or fall events associated with this combination in their practice should document the ACB score, the losartan dose, and the diphenhydramine dose in the patient record, as this supports future pharmacovigilance data.

Clinical Bottom Line

The interaction between losartan and diphenhydramine is real, measurable, and concentration-dependent. In adults under 65 with well-controlled blood pressure, a single 25 mg dose of diphenhydramine for short-term allergy relief may be acceptable with the monitoring and counseling steps described above. In adults aged 65 or older, the 2023 AGS Beers Criteria make the answer clear: avoid diphenhydramine entirely and use a second-generation antihistamine like loratadine 10 mg or an evidence-based non-pharmacological sleep strategy instead. For any patient on losartan/HCTZ (Hyzaar), that same caution applies regardless of age, given the additive volume-depletion risk. The ACB score should be calculated at every medication review, and a score of 3 or above (which diphenhydramine alone achieves) should trigger an automatic reassessment of the full antihypertensive regimen with the prescribing clinician.